Table 3.
Univariate Sensitivity Analysis
| Scenario | Current Value | Lower Bound | Upper Bound |
|---|---|---|---|
| Prevalence of asthma | 7.6% | 6.1% | 9.1% |
| Annual population growth rate | 1.4% | 1.12% | 1.68% |
| Percent treated with asthma controllers | 82.3% | 65.8% | 98.8% |
| Percent treated with at least medium-dose ICS/LABA | 34.2% | 27.4% | 41.0% |
| Percent uncontrolled on at least medium-dose ICS/LABA | 52.5% | 42.0% | 63.0% |
| Price adjustment (mark-up) | 0.0% | 0.0% | 20.0% |
| Co-paya | 0.0 | 0.0 | 20.0 |
| Co-insurancea | 0.0% | 0.0% | 20.0% |
| Adherence rate | Current values | −10.0% | +10.0% |
| FF/UMEC/VI market share | Current values | −50.0% | +100.0% |
Notes: aThe model applied either co-pay or co-insurance via the control settings. Depending on which setting the model used, only one of these rows was displayed in the one-way sensitivity analysis table.
Abbreviations: FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; UMEC, umeclidinium; VI, vilanterol.